Lv1
30 积分 2025-04-08 加入
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
3天前
已完结
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
3天前
已完结
Intestinal dysbiosis exacerbates skin inflammation via microbial metabolite-driven Th2 cell differentiation
8天前
已完结
A New Hope for Treating Podocytopathies
1个月前
已关闭
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
2个月前
已完结
Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in Chronic Kidney Disease
3个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
3个月前
已完结
A Controlled Trial of Combined Therapy for Newly Diagnosed Severe Childhood IgA Nephropathy
5个月前
已关闭
Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy
5个月前
已完结
The Anti-APRIL Antibody Sibeprenlimab Reduces Circulating Immune Complexes in Patients with IgAN: The Phase 2 ENVISION Randomized Controlled Trial
6个月前
已关闭
皖公网安备34019202002308
